Moviprep pulver til oral opløsning Данска - Дански - Lægemiddelstyrelsen (Danish Medicines Agency)

moviprep pulver til oral opløsning

norgine b.v. - ascorbinsyre, kaliumchlorid, macrogol 3350, natriumascorbat, natriumchlorid, natriumsulfat, vandfrit - pulver til oral opløsning

NuvaRing 120+15 mikg/24 timer vaginalindlæg Данска - Дански - Lægemiddelstyrelsen (Danish Medicines Agency)

nuvaring 120+15 mikg/24 timer vaginalindlæg

n.v. organon - ethinylestradiol, etonogestrel - vaginalindlæg - 120+15 mikg/24 timer

Innovair Nexthaler 200+6 mikrog./dosis inhalationspulver Данска - Дански - Lægemiddelstyrelsen (Danish Medicines Agency)

innovair nexthaler 200+6 mikrog./dosis inhalationspulver

chiesi farmaceutici s.p.a. - beclometasondipropionat, formoterolfumarat dihydrat - inhalationspulver - 200+6 mikrog./dosis

Pegasys Европска Унија - Дански - EMA (European Medicines Agency)

pegasys

pharmaand gmbh - peginterferon alfa-2a - hepatitis c, chronic; hepatitis b, chronic - immunostimulants, - chronic hepatitis b adult patients pegasys is indicated for the treatment of hepatitis b envelope antigen (hbeag)-positive or hbeag-negative chronic hepatitis b (chb) in adult patients with compensated liver disease and evidence of viral replication, increased alanine aminotransferase (alt) and histologically verified liver inflammation and/or fibrosis (see sections 4. 4 og 5. paediatric patients 3 years of age and older pegasys is indicated for the treatment of hbeag-positive chb in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum alt levels. med hensyn til beslutningen om at indlede behandling hos pædiatriske patienter, se afsnit 4. 2, 4. 4 og 5. chronic hepatitis c adult patients pegasys is indicated in combination with other medicinal products, for the treatment of chronic hepatitis c (chc) in patients with compensated liver disease (see sections 4. 2, 4. 4 og 5. for at hepatitis c virus (hcv) genotype specifik aktivitet, se afsnit 4. 2 og 5. paediatric patients 5 years of age and older pegasys in combination with ribavirin is indicated for the treatment of chc in treatment-naïve children and adolescents 5 years of age and older who are positive for serum hcv-rna. når det besluttes at indlede behandling i barndommen, er det vigtigt at overveje, væksthæmning, der er fremkaldt af en kombination terapi. reversibilitet af væksthæmning er usikker. beslutningen om at behandling skal ske på grundlag af en individuel vurdering (se afsnit 4.

Signum Vanddispergerbart granulat Данска - Дански - SEGES Landbrug & Fødevarer

signum vanddispergerbart granulat

basf a/s - pyraclostrobin, boscalid - vanddispergerbart granulat - 67 g/kg pyraclostrobin ; 267 g/kg boscalid